# Galcanezumab-Gnlm (Emgality)

Source: https://ourhealthnetwork.com/drugs/galcanezumab-gnlm
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Galcanezumab-Gnlm?

Galcanezumab-Gnlm (brand name: Emgality) is a monoclonal antibodies. It is prescribed to treat cluster headache. Across the United States, 7,000 doctors prescribe Galcanezumab-Gnlm to approximately 18,000 Medicare patients.

## Brand names

Emgality

## Indications

Galcanezumab-Gnlm is primarily prescribed for the treatment of cluster headache.

## Conditions treated

- [Cluster Headache](https://ourhealthnetwork.com/conditions/cluster-headache)

## Mechanism of action

Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

## Drug classification

- Established Pharmacologic Class: monoclonal antibodies
- Route of administration: SUBCUTANEOUS

## Common side effects

adverse reactions (incidence ≥2% and at least 2% greater than placebo) in EMGALITY clinical studies were injection site reactions

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)